These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 26463529

  • 21. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
    Fridrik MA, Jaeger U, Petzer A, Willenbacher W, Keil F, Lang A, Andel J, Burgstaller S, Krieger O, Oberaigner W, Sihorsch K, Greil R.
    Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
    [Abstract] [Full Text] [Related]

  • 22. Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma.
    Nakamura N, Hara T, Shibata Y, Matsumoto T, Nakamura H, Ninomiya S, Kito Y, Kitagawa J, Kanemura N, Goto N, Shiraki M, Miyazaki T, Takeuchi T, Shimizu M, Tsurumi H.
    Ann Hematol; 2015 Dec; 94(12):2043-53. PubMed ID: 26385388
    [Abstract] [Full Text] [Related]

  • 23. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.
    Chiappella A, Tucci A, Castellino A, Pavone V, Baldi I, Carella AM, Orsucci L, Zanni M, Salvi F, Liberati AM, Gaidano G, Bottelli C, Rossini B, Perticone S, De Masi P, Ladetto M, Ciccone G, Palumbo A, Rossi G, Vitolo U, Fondazione Italiana Linfomi.
    Haematologica; 2013 Nov; 98(11):1732-8. PubMed ID: 23812930
    [Abstract] [Full Text] [Related]

  • 24. Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma.
    Arakaki H, Nakazato T, Osada Y, Ito C, Aisa Y, Mori T.
    Ann Hematol; 2017 Jul; 96(7):1225-1226. PubMed ID: 28508175
    [No Abstract] [Full Text] [Related]

  • 25. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
    Linschoten M, Kamphuis JAM, van Rhenen A, Bosman LP, Cramer MJ, Doevendans PA, Teske AJ, Asselbergs FW.
    Lancet Haematol; 2020 Apr; 7(4):e295-e308. PubMed ID: 32135128
    [Abstract] [Full Text] [Related]

  • 26. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma.
    Mori M, Kitamura K, Masuda M, Hotta T, Miyazaki T, Miura AB, Mizoguchi H, Shibata A, Saito H, Matsuda T, Masaoka T, Harada M, Niho Y, Takaku F.
    Int J Hematol; 2005 Apr; 81(3):246-54. PubMed ID: 15814336
    [Abstract] [Full Text] [Related]

  • 27. Dose-dense CHOP plus rituximab (R-CHOP14) for the treatment of elderly patients with high-risk diffuse large B cell lymphoma: a pilot study.
    Rigacci L, Nassi L, Alterini R, Carrai V, Longo G, Bernardi F, Martini V, Bosi A.
    Acta Haematol; 2006 Apr; 115(1-2):22-7. PubMed ID: 16424645
    [Abstract] [Full Text] [Related]

  • 28. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
    Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA.
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468
    [Abstract] [Full Text] [Related]

  • 29. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
    Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A.
    Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
    [Abstract] [Full Text] [Related]

  • 30. Complications and outcomes in diffuse large B-cell lymphoma with gastric lesions treated with R-CHOP.
    Kadota T, Seo S, Fuse H, Ishii G, Itoh K, Yano T, Kaneko K, Tsukasaki K.
    Cancer Med; 2019 Mar; 8(3):982-989. PubMed ID: 30730104
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).
    Jung SH, Lee JJ, Kim WS, Lee WS, Do YR, Oh SY, Kim MK, Mun YC, Shin HJ, Kwak JY, Kang HJ, Won JH, Kwon JH, Park E, Suh C, Yang DH.
    Eur J Haematol; 2015 Jun; 94(6):504-10. PubMed ID: 25288018
    [Abstract] [Full Text] [Related]

  • 33. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
    Zinzani PL, Stefoni V, Finolezzi E, Brusamolino E, Cabras MG, Chiappella A, Salvi F, Rossi A, Broccoli A, Martelli M.
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
    [Abstract] [Full Text] [Related]

  • 34. Transient adrenal insufficiency in diffuse large B cell lymphoma patients after chemotherapy with short-course, high-dose corticosteroids.
    Owattanapanich W, Sirinvaravong S, Suphadirekkul K, Wannachalee T.
    Ann Hematol; 2018 Dec; 97(12):2403-2410. PubMed ID: 30109424
    [Abstract] [Full Text] [Related]

  • 35. [The efficacy and adverse effects of rituximab with CHOP or THP-COP in old-old and extremely old patients with diffuse large B cell lymphoma].
    Kikukawa M, Miyazaki K, Kiuchi A, Abe S, Fujii H, Kanaya K, Shin K, Iwamoto T.
    Nihon Ronen Igakkai Zasshi; 2006 Mar; 43(2):236-40. PubMed ID: 16683659
    [Abstract] [Full Text] [Related]

  • 36. Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma.
    Eyre TA, Salisbury R, Eyre DW, Watson C, Collins GP, Hatton CS.
    Br J Haematol; 2016 May; 173(3):487-91. PubMed ID: 26223361
    [No Abstract] [Full Text] [Related]

  • 37. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
    Choi YW, Jeong SH, Ahn MS, Lee HW, Kang SY, Choi JH, Jin UR, Park JS.
    J Korean Med Sci; 2014 Nov; 29(11):1493-500. PubMed ID: 25408580
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
    Kurita D, Miura K, Nakagawa M, Ohtake S, Sakagami M, Uchino Y, Takahashi H, Kiso S, Hojo A, Kodaira H, Yagi M, Hirabayashi Y, Kobayashi Y, Iriyama N, Kobayashi S, Hatta Y, Kura Y, Sugitani M, Takei M.
    Int J Hematol; 2015 Jun; 101(6):585-93. PubMed ID: 25776837
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.